Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Poised For Growth As It Expands Its Pharma Focus And Accelerates Pipeline

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The Swiss pharma expands its areas of focus in pharmaceuticals to include dedicated units within its pharma business for respiratory, dermatology, heart failure and cell therapy, as its oncologic products continue to advance – its CDK 4/6 inhibitor will enter Phase III this year.

You may also be interested in...



Novartis Trims Its Sails, Divests Blood-Testing Unit To Spain’s Grifols

CEO Joe Jimenez delivers on his strategy to free up resources at Novartis by divesting its non-core blood transfusion diagnostics business for $1.7 billion.

Novartis Seems Close to Consumer Health Sale – Analyst

Novartis CEO Joe Jimenez made clear the firm is considering divesting its consumer product, animal health and vaccines and diagnostics business, Sanford and Bernstein analysts say. “It seems that Novartis will be making final decisions with these units fairly soon,” they say.

IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic

Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS005317

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel